Condition: Small Cell Lung Cancer · Sponsor: Tempus AI
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
This description comes directly from the study's public registry record.
Sculptor Study · 833-514-4187 · sculptor-study@tempus.com
Always discuss trial participation with your own doctor first.
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | Withdrawn |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Illinois Cancer Care | Peoria, Illinois, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Englewood Health Medical Center | Englewood, New Jersey, United States | Withdrawn |
| University of North Carolina | Chapel Hill, North Carolina, United States | Recruiting |
| TriHealth Cancer Institute | Cincinnati, Ohio, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| OhioHealth Research Institute | Columbus, Ohio, United States | Withdrawn |
| Oklahoma Cancer Specialists and Research Institutes | Tulsa, Oklahoma, United States | Withdrawn |
| Cancer Care Association of York | York, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05257551